The digital pill application is rated as a significant step forward in the convergence of health care and technology. The system offers an objective way for doctors to measure whether patients swallow their pills on schedule.
The drug is a drug released by Otsuka Pharmaceutical Co. Ltd. Abilify for schizophrenia, bipolar disorder, and depression. While the app contains a tracking device developed by Proteus Digital Health. Because of this, Otsuka's shares rose 2.5 percent after the news of the US Food and Drug Administration (FDA).
The FDA says that the ability to track the consumption of prescribed medicines for mental illness may be useful for some patients, although the ability of digital pill applications to improve patient compliance has not been proven.
The FDA supports the development and use of new technologies in prescription drugs and is committed to working with companies to understand how technology can benefit patients and prescriptions, Mitchell Mathis of the FDA's Center for FDA's Food and Drug Evaluation said.
This system works by sending a message from a small piston-cut sensors that can be used. Then, transmits the information to the mobile app so that patients can track drug consumption on their smartphone.
The sensor does not have a battery or antenna and is activated from the liquid entering the stomach. It completes the circuit between the copper and magnesium layers on both sides so as to produce a small electrical charge.
In the long run, such digital pill applications can also be used to manage patients with other complicated treatment routines. For example, such as diabetes or heart.
No comments:
Post a Comment